A Pre-Approval Information Exchange (PIE) Webinar sponsored by Servier.

Servier, a global pharmaceutical group, is excited to provide an overview of vorasidenib, an investigational treatment for patients with mIDH glioma. As the potential first-in-class targeted therapy for mIDH glioma, vorasidenib was granted fast track designation by the FDA, with an anticipated PDUFA date in Q3 2024. This webinar will provide an overview of mIDH glioma and highlight the clinical information of vorasidenib.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

The webinar will feature key insights derived from a recent Market Insights roundtable discussion hosted by AMCP, where experts and thought leaders gathered to address the often-overlooked connection between mental health and rare diseases. Our esteemed panelists delved into the challenges faced by individuals coping with rare diseases, explored the impact on their mental well-being, and discussed strategies to improve holistic patient care.

• Gain a better understanding of the current unmet need for mental health services for those with rare disease - Results of a NORD survey of member patient organizations.
• Review how mental health care is currently delivered in the US and identify the gaps that may exist.
• Assess the influence of emerging innovative therapies on mental health.
• Acknowledge current access barriers to mental health and why they exist.
• Evaluate the consequences of untreated mental health concerns on patient outcomes and overall healthcare costs.

This webinar will feature a candid conversation with panelists from AMCP's Market Insights Roundtable on Optimizing the Management of Inherited Blood Disorders, Part 2 - a follow-up program to the 2022 Roundtable. Speakers will provide an overview of the current and evolving coverage and treatment landscapes for Hemophilia, Sickle Cell, and Beta Thalassemia.

Speakers will share insights from the roundtable discussion which includes the effects of recently approved therapies on clinicians, payers, and patients; emerging trends within the stop loss market; potential issues and obstacles related to monitoring and reporting outcomes; and identifying concerns associated with both existing and emerging contracting and reimbursement models. Speakers will also share the findings of a national bleeding disorder center of excellence (COE) survey and managed care insights around coverage and access to treatments for inherited blood disorders.

This webinar is open to AMCP Members only.

Managed care pharmacy and prescription drug coverage is a growing part of the American health care sector. The AMCP report "Access, Affordability, and Outcomes" authored by Heather Bates and Susanna Leaf from Berkeley Research Group (BRG) was created to help build awareness of the existence, prevalence, and importance of managed care pharmacy. We are pleased to invite the authors to share their findings and to discuss how professionals in this field facilitate appropriate access to prescription treatments while remaining mindful of rising costs. Attendees of this webinar will learn more about:

• Pharmacy benefit design and implementation.
• Medication utilization management, such as prior authorization and step therapy.
• Quality and safety program management.
• Promoting affordability and access.

Are you interested in exploring the unique product characteristics of different botulinum toxin type A (BoNT/A) products and the clinical implications of these differences?

Learning Objectives:

• Discuss the different manufacturing processes leading to unique product characteristics of each botulinum toxin.
• Review the different clinical characteristics of each botulinum toxin. 
• Discuss that botulinum toxin units are non-interchangeable.
• Review the clinical value of onabotulinumtoxinA.

Alzheimer's disease (AD) is a growing public health crisis and represents a crucial unmet need in healthcare. New AD diagnostic tools and therapies are evolving the management of AD, changing the patient journey towards earlier identification and treatment initiation.

During this program, we will overview the patient journey to treatment and discuss signs and diagnosis of early AD, the clinical trial data in informing selection for treatment for appropriate patients, key considerations for initiating the treatment, and monitoring for safety.

Program:

• 11am-Noon ET
  Addressing Health Disparities and Advancing Diabetes Management
• 1-2pm ET 
  Diverse Partnerships: Community Health Workers in Managed Care Pharmacy Practice
• 3-4pm ET
  Podium Session - Managed Care Pharmacy Research Highlighting Health Disparities

This webinar will discuss the burden of disease in hemophilia A, provide an overview of current methods of half-life extension for factor VIII replacement therapies, introduce efanesoctocog alfa, and present the results of the Phase 3 XTEND-1 and XTEND-Kids studies.

This educational activity is not accredited for continuing pharmacy education credit.

Market Insights programs form an integral component of AMCP's efforts to identify deeper insights to guide coverage, access, and clinical management decisions. This non-promotional, sponsored webinar will review health plan best practice recommendations for Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC) with an expert panel of oncology and managed care experts.

Given the central role of managed care and payer professionals in enhancing the value and accessibility of cancer care, comprehending the best practices for biomarker testing in NSCLC is paramount. These best practices have been developed through expert interviews, a nationwide survey, and multistakeholder workshop, and are founded on the discoveries from the Market Insights program focused on Bridging the Gaps in Precision Oncology: Opportunities in NSCLC.

During this webinar, our panel of experts will delve into health plan best practices concerning biomarker testing in NSCLC, present the results of a national survey among managed care oncology professionals, and explore the elements of high-quality care that can advance health equity and address unmet needs in NSCLC. Following the presentation, there will be an opportunity to engage with the panelists during a live Q&A session.

Learn About:

At the completion of this activity, participants should be able to:

• Explore health plan practices for biomarker testing in NSCLC
• Discuss key insights from a national managed care oncology survey on biomarker testing in NSCLC
• Examine strategies available to managed care professionals to address known gaps in biomarker testing
• Identify components of high-quality care that improve health equity and address unmet needs in cancer care